Results 201 to 210 of about 326,443 (336)

Real‐World Molecular Analyses May Overestimate Chemotherapy Benefit in HR‐Positive/HER2‐Negative Breast Cancer

Cancer Nexus, EarlyView.
ABSTRACT Large real‐world breast cancer datasets with molecular profiling are increasingly used to estimate the benefit of adjuvant chemotherapy in hormone receptor‐positive, HER2‐negative (HR+/HER2−) disease and are often interpreted alongside randomized trial data.
Mobina Shrestha, Patricia McNally, Priyanka Nagdev, Daniel Cruceta Reynoso, Amir Babu, Muhammad A. Israr   +5 more
wiley   +1 more source

Intratumoral dendritic cell immunotherapy controls dissemination of metastasis-initiating cancer cells, even in patients with metastatic breast cancer. [PDF]

J Immunother Cancer
Soyano A, Lee MC, Han HS, Aldrich A, Soliman H, Olson-Mcpeek SK, Balsay-Patel CN, Aiello P, Farrell CM, Weinfurtner R, Burgos E, Czerniecki BJ, Ramamoorthi G.   +12 more
europepmc   +1 more source

Prognostic Factors Influencing Progression-Free Survival in HER2-Positive Metastatic Breast Cancer Patients Who Were Treated With A Combination of Lapatinib and Capecitabine

, 2023
İzzet Doğan, Nail Paksoy, Naziye Ak, Sezai Vatansever, Pınar Saip, Adnan Aydıner   +5 more
openalex   +1 more source

Optimizing Body Size‐Based Dosing Approaches for Antibody–Drug Conjugates

Clinical Pharmacology &Therapeutics, EarlyView.
Optimized dosing precision of antibody–drug conjugates (ADCs) remains challenging due to narrow therapeutic indices, efficacious doses near the maximum tolerated dose, and substantial interindividual variability in exposure. Body size‐based dosing can reduce exposure variability when the allometric scaling exponent for clearance α = 1 but may over‐ or ...
Andrew B. SyBing, Diane D. Wang
wiley   +1 more source

HER2 [PDF]

, 2019
openaire   +1 more source

Interaction of cytokeratin 19 head domain and HER2 in the cytoplasm leads to activation of HER2-Erk pathway [PDF]

, 2016
Tomoaki Ohtsuka, Masakiyo Sakaguchi, Hiromasa Yamamoto, Shuta Tomida, Katsuyoshi Takata, Kazuhiko Shien, Shinsuke Hashida, Tomoko Miyata‐Takata, Mototsugu Watanabe, Ken Suzawa, Junichi Soh, Youyi Chen, Hiroki Sato, Kei Namba, Hidejiro Torigoe, Kazunori Tsukuda, Tadashi Yoshino, Shinichiro Miyoshi, Shinichi Toyooka   +18 more
openalex   +1 more source

Longitudinal Tumor Size and Survival Modeling for Exposure–Response Analysis of Drugs with Frequent Dose Reductions: Dose Justification of Abemaciclib in Patients with Metastatic Breast Cancer

Clinical Pharmacology &Therapeutics, EarlyView.
Abemaciclib is an oral anticancer drug indicated for treatment of HR+ HER2‐ breast cancer. Dose modifications due to side effects are frequent, thus drug exposures change over time as a result of altering the dose or temporarily withholding abemaciclib treatment.
Emmanuel Chigutsa, Sonya C. Chapman, P. Kellie Turner   +2 more
wiley   +1 more source

Response to trastuzumab-deruxtecan in metastatic triple-negative breast cancer with both HER2 mutation and low expression. [PDF]

Einstein (Sao Paulo)
Amarger CD, Rabello MIS, Skaf SC, Moura F, Cassoli JPB, Taranto P, Serrano Usón Junior PL, Kaliks R, Beal JR.   +8 more
europepmc   +1 more source

241P Criteria for decision-making in adjuvant therapy for HR+/HER2- early breast cancer in clinical routine in Germany

D. Finas, Thomas Fietz, K. Engelken, H. Eisenbraun, Frantisek Sandor, B. Kuppinger, J Heim, Claudia Quiering, C. Roos, Amber M. Froehlich, Marie‐Paule Thill   +10 more
openalex   +1 more source

Prognosis and chemotherapy efficacy in small-tumor breast cancer with different immune subtypes: a SEER-based study. [PDF]

Transl Cancer Res
Wang HM, Zhou YH, Lin GB, Zheng BL, Zhang K, Chi XR, Peng Y, Huang XX, Zhang HL.   +8 more
europepmc   +1 more source